Altamira Therapeutics Ltd. (CYTO)

Altamira Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	3	1	4	25	13	3
Market Cap Growth	-94.41%	-66.55%	-83.29%	86.82%	336.42%	37.69%
Enterprise Value	2	1	11	24	1	2
PE Ratio	-	-0.30	-0.14	-1.32	-1.42	-0.44
PB Ratio	0.37	0.18	-0.46	1.73	0.70	0.49
P/FCF Ratio	-0.10	-0.10	-0.44	-1.65	-2.41	-0.35
P/OCF Ratio	-0.10	-0.10	-0.44	-1.65	-2.41	-0.35
EV/EBITDA Ratio	-0.31	-0.31	-0.40	-1.29	-0.12	-0.23
EV/EBIT Ratio	-0.29	-0.29	-0.40	-1.29	-0.11	-0.23
EV/FCF Ratio	-0.06	-0.06	-1.17	-1.62	-0.19	-0.18
Debt / Equity Ratio	0.02	0.02	-0.76	0.04	0.03	-
Debt / EBITDA Ratio	-0.05	-0.05	-0.25	-0.03	-0.06	-
Debt / FCF Ratio	-0.01	-0.01	-0.73	-0.04	-0.11	-
Quick Ratio	0.78	0.78	0.06	0.35	3.74	0.76
Current Ratio	1.38	1.38	0.14	0.84	3.83	1.04
Interest Coverage	-1.32	-1.32	-20.91	-1216.15	-59.83	-237.43
Return on Equity (ROE)	416.90%	416.90%	-1123.70%	-114.50%	-71.90%	-136.90%
Return on Assets (ROA)	-55.30%	-55.30%	-208.30%	-85.40%	-54.60%	-69.40%
Return on Capital (ROIC)	-90.21%	-90.21%	908.18%	-50.48%	-31.82%	-120.26%
Earnings Yield	-171.34%	-332.82%	-689.33%	-75.70%	-70.30%	-225.11%
FCF Yield	-482.22%	-990.15%	-225.63%	-60.68%	-41.52%	-287.06%
Buyback Yield / Dilution	-1066.00%	-832.23%	-25.08%	-169.67%	-169.85%	-674.71%
Total Shareholder Return	-1066.00%	-832.23%	-25.08%	-169.67%	-169.85%	-674.71%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).